We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
From discovery to real-world impact, VDEC equips scientists with the expertise and facilities to navigate each step in the development of vaccines and therapeutics.
Public and construction trade vigilance needed as greatest risk period for oak processionary moth (OPM) begins.
For manufacturers reporting adverse incidents with intraocular lenses under the vigilance system.
Device-specific guidance for manufacturers on reporting adverse incidents under the vigilance system
How to minimise your risk, and what to do if there's a terrorist attack.
VDEC’s Discovery and surveillance capabilities provide unique services across a spectrum of molecular immunology platforms.
Advice for British nationals on staying safe when travelling by sea
For manufacturers reporting adverse incidents with biological/mechanical surgical heart valves under the vigilance system.
For manufacturers reporting adverse incidents with IVC filters under the vigilance system.
Information about the eight-toothed spruce bark beetle, including how to report sightings.
Advice for manufacturers of Class I medical devices for placing products on the UK market
FCDO travel advice for Colombia. Includes safety and security, insurance, entry requirements and legal differences.
Government led recommendations made by Part 1 of the independent Angiolini Inquiry have been accepted.
How marketing authorisation holders should inform MHRA of a signal or an ADR to a medicine.
How we evaluated pre-exposure prophylactic (preventative) treatments for COVID-19.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).